Pricing wars heat up over hepatitis C drugs By: CNBC.com News February 04, 2015 at 12:13 PM EST Discounts on Gilead's hepatitis C drugs this year will be 46 percent, way more than investors and analysts expected. Read More >> Related Stocks: AbbVie Achison Inc Amgen Bristol-Myers Squibb CVS Health Corp Express Scripts Holding Gilead Sciences Merck & Co Regeneron Pharmaceuticals Wells Fargo